Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs ZYDUS LIFESCIENCES - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA ZYDUS LIFESCIENCES GSK PHARMA/
ZYDUS LIFESCIENCES
 
P/E (TTM) x 62.2 34.2 181.8% View Chart
P/BV x 18.9 5.8 327.0% View Chart
Dividend Yield % 1.6 0.6 275.9%  

Financials

 GSK PHARMA   ZYDUS LIFESCIENCES
EQUITY SHARE DATA
    GSK PHARMA
Mar-23
ZYDUS LIFESCIENCES
Mar-23
GSK PHARMA/
ZYDUS LIFESCIENCES
5-Yr Chart
Click to enlarge
High Rs1,684495 340.2%   
Low Rs1,231319 385.3%   
Sales per share (Unadj.) Rs191.9170.3 112.7%  
Earnings per share (Unadj.) Rs35.919.8 181.4%  
Cash flow per share (Unadj.) Rs39.826.9 147.7%  
Dividends per share (Unadj.) Rs32.006.00 533.3%  
Avg Dividend yield %2.21.5 149.0%  
Book value per share (Unadj.) Rs102.9173.0 59.5%  
Shares outstanding (eoy) m169.411,012.20 16.7%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x7.62.4 317.5%   
Avg P/E ratio x40.620.6 197.3%  
P/CF ratio (eoy) x36.715.1 242.3%  
Price / Book Value ratio x14.22.4 601.9%  
Dividend payout %89.230.3 294.1%   
Avg Mkt Cap Rs m246,858412,144 59.9%   
No. of employees `000NANA-   
Total wages/salary Rs m5,95024,564 24.2%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m32,517172,374 18.9%  
Other income Rs m1,0074,746 21.2%   
Total revenues Rs m33,524177,120 18.9%   
Gross profit Rs m8,03329,677 27.1%  
Depreciation Rs m6587,227 9.1%   
Interest Rs m181,299 1.4%   
Profit before tax Rs m8,36425,897 32.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,2885,878 38.9%   
Profit after tax Rs m6,07620,019 30.4%  
Gross profit margin %24.717.2 143.5%  
Effective tax rate %27.422.7 120.5%   
Net profit margin %18.711.6 160.9%  
BALANCE SHEET DATA
Current assets Rs m24,943100,082 24.9%   
Current liabilities Rs m13,26455,267 24.0%   
Net working cap to sales %35.926.0 138.1%  
Current ratio x1.91.8 103.8%  
Inventory Days Days9750 193.4%  
Debtors Days Days21694 230.9%  
Net fixed assets Rs m6,988144,776 4.8%   
Share capital Rs m1,6941,012 167.4%   
"Free" reserves Rs m15,735174,146 9.0%   
Net worth Rs m17,430175,158 10.0%   
Long term debt Rs m00-   
Total assets Rs m31,930244,940 13.0%  
Interest coverage x462.620.9 2,209.5%   
Debt to equity ratio x00-  
Sales to assets ratio x1.00.7 144.7%   
Return on assets %19.18.7 219.3%  
Return on equity %34.911.4 305.0%  
Return on capital %48.115.5 309.7%  
Exports to sales %039.2 0.0%   
Imports to sales %48.111.9 403.3%   
Exports (fob) Rs mNA67,577 0.0%   
Imports (cif) Rs m15,63020,544 76.1%   
Fx inflow Rs m1,62267,577 2.4%   
Fx outflow Rs m15,63020,544 76.1%   
Net fx Rs m-14,00847,033 -29.8%   
CASH FLOW
From Operations Rs m4,84226,888 18.0%  
From Investments Rs m8,07911,712 69.0%  
From Financial Activity Rs m-15,433-44,004 35.1%  
Net Cashflow Rs m-2,512-5,338 47.1%  

Share Holding

Indian Promoters % 0.0 75.0 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 11.6 18.0 64.2%  
FIIs % 2.9 5.0 58.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.0 25.0 99.9%  
Shareholders   114,663 306,495 37.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   DIVIS LABORATORIES    CIPLA    SUN PHARMA    DR. REDDYS LAB    MANKIND PHARMA    


More on GSK Pharma vs Cadila Healthcare

No comparison is complete without understanding how the stock prices have performed over a period of time.

Here's a brief comparison:

GSK Pharma vs Cadila Healthcare Share Price Performance

Period GSK Pharma Cadila Healthcare S&P BSE HEALTHCARE
1-Day 3.26% 0.57% 1.18%
1-Month -9.77% 7.77% -0.75%
1-Year 52.63% 107.52% 61.82%
3-Year CAGR 10.89% 32.30% 18.16%
5-Year CAGR 8.44% 24.52% 19.79%

* Compound Annual Growth Rate

Here are more details on the GSK Pharma share price and the Cadila Healthcare share price.

Moving on to shareholding structures...

The promoters of GSK Pharma hold a 75.0% stake in the company. In case of Cadila Healthcare the stake stands at 75.0%.

To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of GSK Pharma and the shareholding pattern of Cadila Healthcare.

Finally, a word on dividends...

In the most recent financial year, GSK Pharma paid a dividend of Rs 32.0 per share. This amounted to a Dividend Payout ratio of 89.2%.

Cadila Healthcare paid Rs 6.0, and its dividend payout ratio stood at 30.3%.

You may visit here to review the dividend history of GSK Pharma, and the dividend history of Cadila Healthcare.

For a sector overview, read our pharmaceuticals sector report.



Today's Market

Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising(Closing)

After opening the day on positive note, Indian share markets gained the momentum as the session progressed and ended on firm footing.